Almac One™ would help sponsors to face the challenges existing in the drug development market

It provide a single set of process to sponsors and enable greater visibility and control of supply chain

Reports confirm that Almac Group has recently introduced Almac One™, the first unified Clinical Trial Solution, for redefining the experience of a clinical supply chain and create an end-to-end responsive process which would enhance the accuracy and visibility across the clinical study lifecycle.

The company has stated that the drug development market is continuously evolving with common challenges faced, like limited inventory, expensive investigational products as well as globalization of clinical trials. Supposedly, a key difficulty which sponsors are facing today is the disconnect existing throughout the clinical supply chain owing to variable recruitment patterns and demand from patients, leading to costly and disjointed trials with frequently missed targets.

According to an Almac Group press release, the company has leveraged more than thirty years of experience in Clinical Supplies delivery and services, along with Interactive Response Technology for developing Almac One™. It also aimed to fulfil the need for more smart, informed and timely decision making for aligning vital study data.

Almac mentioned that the Almac One™ solution brings together expert consultants from across the clinical logistics, packaging and IRT spectrum to offer a single set of process to sponsors, in combination with close-loop technology for managing data end-to-end which enables greater visibility and control in a supply chain across a study’s lifecycle. This is achieved by the alignment of patient recruitment, clinical IRT and supply strategies for delivering a seamless flow of data. 

Managing Director and President of Almac Clinical Technologies, Val Higgins said that Almac One™ would offer sponsors a more streamlined approach towards global supply chain and will empower clients to make faster, more accurate decisions for managing their studies. He added that the company’s latest development is a part of its ongoing program of solutions targeted at helping clients face the challenges which clinical supply chain may bring in the future.